PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 5, 2026American Society of Clinical Oncology Educational Book2 citations

Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Evidence and Future Directions

Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRana R. McKayATAsha TipirneniRBR. Bangs

Discussion

Loading...

Member takes

Overview

This chapter examines neoadjuvant therapy outcomes in genitourinary cancers, suggesting new strategies for better patient care.

Key Points

  • The aim is to evaluate the effectiveness of neoadjuvant systemic therapies in kidney and bladder cancer and explore future approaches.
  • Reviewed current evidence on neoadjuvant therapies and their impact on pathologic responses.
  • Analyzed ongoing studies assessing novel adjuvant strategies based on circulating tumor DNA.
  • Discussed the role of artificial intelligence in enhancing diagnostic and prognostic capabilities.
  • Cisplatin-based chemotherapy shows pathologic complete response as a potential survival indicator in bladder cancer.
  • Limited pathologic responses observed in early trials with tyrosine kinase inhibitor monotherapy for renal cell carcinoma.
  • Safe combinations of immune checkpoint inhibitors demonstrated feasibility and pathologic response.

Cite This Study

McKay et al. (2026) studied this question.

synapsesocial.com/papers/69a91d8dd6127c7a504c05e4https://doi.org/10.1200/edbk-26-516902
View Full Paper
Ask AI
Bookmark
Share